Pentasa 500 Mg 500 mg Tablets

Pentasa 500 Mg 500 mg Tablets

S3
PDF Leaflet Revision Date: 7 January 2026

API: Mesalazine | Company: Ferring

Clinical Summary

Quick overview from the medicine insert

Indication

Treatment of mild to moderate ulcerative colitis.

Dosage (summary)

Adults: Up to 4 g once daily for active disease; 2 g once daily for maintenance.

Special Populations

  • Elderly
  • Children 6-18 years

Pregnancy & Breastfeeding

Use with caution; limited data show no increase in congenital malformations.

Key Drug Interactions

  • Increased risk of blood dyscrasia with azathioprine
  • May decrease warfarin effect

Contraindications

  • Hypersensitivity to mesalazine
  • Severe liver impairment
  • Severe renal impairment (GFR < 30 mL/min)

Common side effects

  • Diarrhoea
  • Nausea
  • Abdominal pain
  • Headache
  • Rash

Counselling Points

  • Do not crush or chew tablets
  • Report any signs of hypersensitivity
  • Ensure adequate fluid intake

Serious warnings

  • Severe cutaneous adverse reactions
  • Monitor renal function
  • Risk of blood dyscrasias
Important Disclaimer

The Pentasa 500 Mg 500 mg Tablets professional information leaflet below is the property of Ferring and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

Healthcare Professionals Only

This content is for registered healthcare professionals

Sign in or create a free account to read the full package insert.

Free for HPCSA-registered professionals. Powered by Medinsert.

Successfully Stashed! 💊

This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

View My Favourites